Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 2
1960 4
1961 2
1962 2
1963 2
1964 5
1965 2
1966 8
1967 4
1968 4
1969 11
1970 23
1971 15
1972 16
1973 20
1974 16
1975 27
1976 24
1977 26
1978 34
1979 39
1980 39
1981 41
1982 30
1983 38
1984 55
1985 55
1986 56
1987 53
1988 67
1989 54
1990 64
1991 59
1992 70
1993 107
1994 101
1995 107
1996 99
1997 115
1998 102
1999 109
2000 112
2001 142
2002 159
2003 158
2004 181
2005 182
2006 243
2007 238
2008 250
2009 250
2010 313
2011 351
2012 348
2013 409
2014 428
2015 457
2016 464
2017 526
2018 506
2019 516
2020 592
2021 604
2022 641
2023 643
2024 585
2025 575
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,352 results

Results by year

Filters applied: . Clear all
Page 1
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Among authors: chan sl. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: chan sl. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Van Dao T, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Paskow MJ, Ran D, Xynos I, Kurland JF, Negro A, Abou-Alfa GK. Rimassa L, et al. Among authors: chan sl. J Hepatol. 2025 Oct;83(4):899-908. doi: 10.1016/j.jhep.2025.03.033. Epub 2025 Apr 11. J Hepatol. 2025. PMID: 40222621 Free article. Clinical Trial.
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.
Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, Schwartz ME, Finn RS, Seong J, Wang XW, Paradis V, Abou-Alfa GK, Rimassa L, Kao JH, Zhang BH, Llovet JM, Bruix J, Yip TC, Wong VW, Wong GL, Chan LL, Liu MQ, Gao Q, Shen F, Kelley RK, Cheng AL, Kurosaki M, Toyoda H, Chen WX, Murakami T, Liang P, Zucman-Rossi J, Minami Y, Miyayama S, Wang K, Man K, Hasegawa K, Li Q, Tsuchiya K, Xu L, Chew V, Chow P, Hoshida Y, Lujambio A, Ng IO, Sakamoto M, Park YN, Yau T, Kudo M, Fan J, Zhou J. Chan SL, et al. Lancet. 2025 Aug 16;406(10504):731-778. doi: 10.1016/S0140-6736(25)01042-6. Epub 2025 Jul 28. Lancet. 2025. PMID: 40744051 Review. No abstract available.
Lysosomal dysfunction and inflammatory sterol metabolism in pulmonary arterial hypertension.
Harvey LD, Alotaibi M, Tai YY, Tang Y, Kim HJ, Kelly NJ, Sun W, Woodcock CC, Arshad S, Culley MK, El Khoury W, Xie R, Al Aaraj Y, Zhao J, Hafeez N, Rao RJ, Jiang S, Negi V, Kirillova A, Perk D, Watson AM, St Croix CM, Stolz DB, Lee JY, Cheng MH, Zhang M, Detmer S, Guzman E, Manan RS, Saggar R, Haley KJ, Waxman AB, Okawa S, Schwantes-An TH, Pauciulo MW, Wang B, Webb A, Chauvet C, Anderson DG, Nichols WC, Desai AA, Lafyatis R, Nouraie SM, Wu H, McDonald JG, Cheng S, Bahar I, Bertero T, Benza RL, Jain M, Chan SY. Harvey LD, et al. Among authors: chan sy. Science. 2025 Jan 24;387(6732):eadn7277. doi: 10.1126/science.adn7277. Epub 2025 Jan 24. Science. 2025. PMID: 39847635 Free PMC article.
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Vogel A, Chan SL, Dawson LA, Kelley RK, Llovet JM, Meyer T, Ricke J, Rimassa L, Sapisochin G, Vilgrain V, Zucman-Rossi J, Ducreux M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Vogel A, et al. Among authors: chan sl. Ann Oncol. 2025 May;36(5):491-506. doi: 10.1016/j.annonc.2025.02.006. Epub 2025 Feb 20. Ann Oncol. 2025. PMID: 39986353 No abstract available.
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Among authors: chan sl. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798579 Free PMC article. Clinical Trial.
Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs.
Hosseini M, Voisin V, Chegini A, Varesi A, Cathelin S, Ayyathan DM, Liu ACH, Yang Y, Wang V, Maher A, Grignano E, Reisz JA, D'Alessandro A, Young K, Wu Y, Fiumara M, Ferrari S, Naldini L, Gaiti F, Pai S, Egan G, Schimmer AD, Bader GD, Dick JE, Xie SZ, Trowbridge JJ, Chan SM. Hosseini M, et al. Among authors: chan sm. Nature. 2025 Jun;642(8067):421-430. doi: 10.1038/s41586-025-08871-w. Epub 2025 Apr 16. Nature. 2025. PMID: 40240595
Pericardial effusions and sotatercept therapy in pulmonary arterial hypertension: a multicentre, real-world experience.
Sahay S, Villasmil Hernandez N, Al Aaraj Y, Argula RG, Bernardo RJ, Chavarria M, Ibecheozor C, Coons JC, Domsic RT, Fortin T, Goodrich-Harris A, Hickey G, Ho T, Kliner J, Machado RF, Rajagopal S, Risbano MG, Sese DG, Thenappan T, Chan SY. Sahay S, et al. Among authors: chan sy. Eur Respir J. 2025 Oct 7;66(4):2501040. doi: 10.1183/13993003.01040-2025. Print 2025 Oct. Eur Respir J. 2025. PMID: 40774808 No abstract available.
Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis.
Meyer A, Chan SSM, Touvier M, Julia C, Tjønneland A, Kyrø C, Dahm CC, Katzke VA, Schulze MB, Tumino R, Sacerdote C, Masala G, Oldenburg B, Guevara M, Bujanda L, Cabrera Castro NA, Tong TYN, Heath AK, Deschasaux-Tanguy M, Hercberg S, Galan P, Mahamat-Saleh Y, Severi G, Carbonnel F, Amiot A. Meyer A, et al. Among authors: chan ssm. Aliment Pharmacol Ther. 2025 Mar;61(6):1032-1042. doi: 10.1111/apt.18497. Epub 2025 Jan 16. Aliment Pharmacol Ther. 2025. PMID: 39817326
10,352 results
You have reached the last available page of results. Please see the User Guide for more information.